See more : Art’s-Way Manufacturing Co., Inc. (ARTW) Income Statement Analysis – Financial Results
Complete financial analysis of Arcutis Biotherapeutics, Inc. (ARQT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcutis Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DuoLun Technology Corporation Ltd. (603528.SS) Income Statement Analysis – Financial Results
- HilleVax, Inc. (HLVX) Income Statement Analysis – Financial Results
- Tapinator, Inc. (TAPM) Income Statement Analysis – Financial Results
- PacificHealth Laboratories, Inc. (PHLI) Income Statement Analysis – Financial Results
- Bathurst Metals Corp. (BMVVF) Income Statement Analysis – Financial Results
Arcutis Biotherapeutics, Inc. (ARQT)
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.99M | 754.00K | 763.00K | 455.00K | 195.00K | 0.00 | 0.00 |
| Gross Profit | 54.62M | 2.93M | -763.00K | -455.00K | -195.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 91.63% | 79.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M | 3.41M |
| General & Administrative | 0.00 | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Other Expenses | 0.00 | 5.82M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Operating Expenses | 295.72M | 304.56M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Cost & Expenses | 300.71M | 305.31M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Interest Income | 0.00 | 9.83M | 173.00K | 967.00K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 29.71M | 15.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 1.25M | 763.00K | 455.00K | 195.00K | 19.74M | 4.11M |
| EBITDA | -227.43M | -294.55M | -205.59M | -135.22M | -41.80M | 480.00K | -872.00K |
| EBITDA Ratio | -381.56% | -8,025.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.74M | -4.11M |
| Operating Income Ratio | -404.49% | -8,183.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -17.93M | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Income Before Tax | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Income Before Tax Ratio | -434.57% | -8,449.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.11M | 9.83M | -454.00K | -84.30K | 23.14K | -480.00K | -4.11M |
| Net Income | -262.14M | -321.29M | -205.90M | -135.68M | -42.00M | -19.26M | -4.98M |
| Net Income Ratio | -439.79% | -8,716.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| EPS Diluted | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| Weighted Avg Shares Out | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
| Weighted Avg Shares Out (Dil) | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
The 7 Best Under $10 Stocks to Buy in July 2024
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks? Cipher Mining Works On A New Base
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
Source: https://incomestatements.info
Category: Stock Reports